Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients

Table 3 Negative agreement of T-Track® CMV, QuantiFERON®-CMV and iTAg™ MHC Tetramers with CMV serology in hemodialysis patients

Test	CMV negative serology^a	CMI-	CMI+	negative agreement	95% CI
T-Track® CMV	57	45	12	0.789	0.661–0.886
CMV aIE-1	57	45	12	0.789	0.661–0.886
CMV app65	57	56	1	0.982	0.906–1.000
QuantiFERON®-CMV^b	55	48	7	0.873	0.755–0.947
iTAg™ MHC Tetramers	45	42	3	0.933	0.817–0.986

^aCMV-serology served as primary reference measurement procedure; ^bcalculation of the negative agreement and associated 95% CI do not take into account the 2 indeterminate QuantiFERON®-CMV results out of the 57 CMV-seronegative patients; CMI- negative test result, CMI+ positive test result, CI confidence interval

ISSN: 1471-2172